---
title: "中國同輻附屬改良新藥臨牀試驗申請獲批"
description: "中國同輻的附屬公司中核海得威研發的改良新藥「注射用硼 [10B] 法侖」臨牀試驗申請獲國家藥品監督管理局批准。該藥物針對頭頸部腫瘤具有顯著臨牀優勢，療程短，毒副作用低。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270402848.md"
published_at: "2025-12-21T11:17:04.000Z"
---

# 中國同輻附屬改良新藥臨牀試驗申請獲批

> 中國同輻的附屬公司中核海得威研發的改良新藥「注射用硼 [10B] 法侖」臨牀試驗申請獲國家藥品監督管理局批准。該藥物針對頭頸部腫瘤具有顯著臨牀優勢，療程短，毒副作用低。

中國同輻 (01763.HK) 公佈，國家藥品監督管理局藥品審評中心官網信息顯示，附屬中核海得威自主研發的 2.2 類改良新藥「注射用硼 \[10B\] 法侖」(BNCT 硼藥：硼中子俘獲療法) 臨牀試驗申請獲批。

「注射用硼 \[10B\] 法侖」針對對放化療不敏感、複發性、難治性、浸潤性、中晚期、局部轉移的頭頸部腫瘤具有顯着臨牀優勢，且治療療程短 (僅需 1-2 次)、毒副作用低。

### Related Stocks

- [01763.HK - 中國同輻](https://longbridge.com/zh-HK/quote/01763.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China Isotope & Radiation Corporation and CNNC Capital Sign Strategic Cooperation Agreement | China Isotope & Radiation Corporation (CIRC) and CNNC Capital Holdings Limited have signed a strategic cooperation agree | [Link](https://longbridge.com/zh-HK/news/267624056.md) |
| Henlius Biotech Get China Nod for Trial Application of Multiple Myeloma Drug | Henlius Biotech Get China Nod for Trial Application of Multiple Myeloma Drug | [Link](https://longbridge.com/zh-HK/news/275731047.md) |
| 23:18 ETNovel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF | Shanghai Ark Biopharmaceutical Co., Ltd. announced that the FDA has cleared its IND application for AK3280, a novel anti | [Link](https://longbridge.com/zh-HK/news/275698481.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-HK/news/275851575.md) |
| Hi Sun Technology to Record HK$100 Million Impairment Loss on Megahunt Investment | Hi Sun Technology (China) Limited anticipates a non-cash impairment loss of approximately HK$100 million on its investme | [Link](https://longbridge.com/zh-HK/news/275584607.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。